Top Markets
Coin of the day
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
株式のランク #27038
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
株価
$1.48
最終同期: 2023-05-31
時価総額
$35.54M
変化(1日)
-5.73%
変化(1年)
0.00%
US
取引 TCR2 Therapeutics Inc. (TCRR)

カテゴリー

TCR2 Therapeutics Inc.(TCRR)の株価履歴
終値の最高値: $1.83 (2023-05-01)

終値の最安値: $16.51 (2019-02-01)
TCR2 Therapeutics Inc. の株価履歴(2019 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2023 73.43%
2022 -78.52%
2021 -83.60%
2020 79.84%
2019 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$552.07 39.99%
US
$168.77 527.63%
US
$1.03K 56.22%
NL
$120.74 -14.98%
AU
$756.93 6.35%
CH